


Company Registration No 4269261 (England and Wales)

**RICHMOND PHARMACOLOGY LIMITED**  
**DIRECTORS' REPORT AND FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2010**

MONDAY



\*L5RFVXL\*

LD2

18/07/2011

109

COMPANIES HOUSE

# **RICHMOND PHARMACOLOGY LIMITED**

## **COMPANY INFORMATION**

---

**Directors**

Dr R Arezina  
Dr J Taubel  
Dr U Lorch  
Mr M Vaughan

**Secretary**

Dr R Arezina

**Company number**

4269261

**Registered office**

Ground Floor  
Interpower House  
Windsor Way  
Aldershot  
Hampshire  
GU11 1JG

**Auditors**

RSM Tenon Audit Limited  
66 Chiltern Street  
London  
W1U 4JT

---

# **RICHMOND PHARMACOLOGY LIMITED**

## **CONTENTS**

---

	<b>Page</b>
Directors' report	1 - 2
Independent auditors' report	3 - 4
Profit and loss account	5
Balance sheet	6
Cash flow statement	7
Notes to the cash flow statement	8 - 9
Notes to the financial statements	10 - 19

---

# **RICHMOND PHARMACOLOGY LIMITED**

## **DIRECTORS' REPORT**

### **FOR THE YEAR ENDED 31 DECEMBER 2010**

---

The directors present their report and financial statements for the year ended 31 December 2010

#### **Principal activities and review of the business**

The principal activity of the company continues to be that of the clinical development of drugs on behalf of pharmaceutical companies

Now in its tenth year we are pleased to report strong financial results for the company Revenue increased by 21% to £11.8m, gross profit increased by 24% to £4,289k and net profit increased by 28% to £408k Net interest continued to decline as loan balances reduced

There were no changes to the facilities during the year, we continue to operate from the two university hospital sites of St Georges and Croydon University (previously Mayday), both in South London We were very pleased to work with several new clients globally during the year which has added to the growing client base of what is now a firmly established company in its field

RPL continues to focus on 4 key areas of Early Phase Studies, First Time Into Human, Thorough QT (TQT) Studies, Bridging Studies and the recruitment of Patients into early phase Studies The business moves into 2011 with good prospects for the year ahead

In 2010 we continued to develop our training management software tool which is used extensively throughout the company Whilst it is not yet available to third parties it is planned to make this product commercially available at a future date The core module is used to manage, monitor and assess training within a company to ensure compliance with relevant statutory requirements

Risks facing the business are assessed by the board from time to time Project risk is assessed by the executive directors prior to the "green light sign off" process which is mandatory before the start of any trial Risk mitigation strategies are put in place where necessary and are reviewed regularly Prices were increased at the start of year in line with labour inflation, liquidity and cash flow have been good taking into consideration the general economic climate during the year

The Directors are pleased to announce that during 2010 Richmond Pharmacology was re-accredited (Standard and Supplementary status) by the MHRA This gives us the continuing opportunity to conduct trials which unaccredited units would not be able to perform

As previously reported, Professor Brian Prichard, Chairman of Richmond Pharmacology's Scientific Advisory Board and non-Executive Board Director died on 6 April 2010 at St George's Hospital in Tooting He was 77 years old The Board are very grateful to Professor Prichard for sharing his knowledge and enjoyment of clinical pharmacology and the significant contribution he made to the Company since its formation

[www.richmondpharmacology.com](http://www.richmondpharmacology.com)

#### **Results and dividends**

The results for the year are set out on page 5

#### **Directors**

The following directors have held office since 1 January 2010

Dr R Arezina

Dr J Taubel

Dr U Lorch

Prof B Prichard

(Deceased 6 April 2010)

Mr L Levine

(Resigned 15 July 2010)

# RICHMOND PHARMACOLOGY LIMITED

## DIRECTORS' REPORT (CONTINUED)

**FOR THE YEAR ENDED 31 DECEMBER 2010**

---

Mr M Levine  
Mr M Vaughan

(Resigned 15 July 2010)

### **Directors' responsibilities**

The directors are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and United Kingdom Generally Accepted Accounting Practice

Company law requires the directors to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing those financial statements, the directors are required to

- select suitable accounting policies and then apply them consistently,
- make judgments and estimates that are reasonable and prudent,
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business

The directors are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities


### **Statement of disclosure to auditors**

So far as the directors are aware, there is no relevant audit information of which the company's auditors are unaware. Additionally, the directors have taken all the necessary steps that they ought to have taken as directors in order to make themselves aware of all relevant audit information and to establish that the company's auditors are aware of that information

By order of the board

Dr R Arezina  
Secretary

12 July 2011



# **RICHMOND PHARMACOLOGY LIMITED**

## **INDEPENDENT AUDITORS' REPORT**

### **TO THE MEMBERS OF RICHMOND PHARMACOLOGY LIMITED**

---

We have audited the financial statements of Richmond Pharmacology Limited for the year ended 31 December 2010 set out on pages 5 to 19. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

#### **Respective responsibilities of directors and auditors**

As explained more fully in the Directors' Responsibilities Statement set out on pages 1 - 2, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view. Our responsibility is to audit and express an opinion on the financial statements in accordance with applicable law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Auditing Practices Board's Ethical Standards for Auditors.

#### **Scope of the audit of the financial statements**

An audit involves obtaining evidence about the amounts and disclosures in the financial statements sufficient to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or error. This includes an assessment of whether the accounting policies are appropriate to the company's circumstances and have been consistently applied and adequately disclosed, the reasonableness of significant accounting estimates made by the directors, and the overall presentation of the financial statements. In addition, we read all the financial and non-financial information in the Directors' Report to identify material inconsistencies with the audited financial statements. If we become aware of any apparent material misstatements or inconsistencies we consider the implications for our report.

#### **Opinion on financial statements**

In our opinion the financial statements

- give a true and fair view of the state of the company's affairs as at 31 December 2010 and of its profit for the year then ended,
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice, and
- the financial statements have been properly prepared in accordance with the Companies Act 2006, and

#### **Opinion on other matter prescribed by the Companies Act 2006**

In our opinion the information given in the Directors' Report for the financial year for which the financial statements are prepared is consistent with the financial statements.

# RICHMOND PHARMACOLOGY LIMITED

## INDEPENDENT AUDITORS' REPORT (CONTINUED)

### TO THE MEMBERS OF RICHMOND PHARMACOLOGY LIMITED

---

#### Matters on which we are required to report by exception

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us, or
- the financial statements are not in agreement with the accounting records and returns, or
- certain disclosures of directors' remuneration specified by law are not made, or
- we have not received all the information and explanations we require for our audit

*RSM Tenon Audit Ltd*

Tony Castagnetti (Senior Statutory Auditor)  
for and on behalf of RSM Tenon Audit Limited

*14/7/2011*

Statutory Auditor

66 Chiltern Street  
London  
W1U 4JT

# RICHMOND PHARMACOLOGY LIMITED

## PROFIT AND LOSS ACCOUNT

FOR THE YEAR ENDED 31 DECEMBER 2010

---

	Notes	2010 £	2009 £
Turnover	2	11,758,343	9,713,024
Cost of sales		(7,469,357)	(6,246,153)
<b>Gross profit</b>		<b>4,288,986</b>	<b>3,466,871</b>
Administrative expenses		(3,872,221)	(3,133,628)
<b>Operating profit</b>	3	<b>416,765</b>	<b>333,243</b>
Other interest receivable and similar income	4	-	316
Interest payable and similar charges	5	(8,617)	(15,283)
<b>Profit on ordinary activities before taxation</b>		<b>408,148</b>	<b>318,276</b>
Tax on profit on ordinary activities	6	-	-
<b>Profit for the year</b>	14	<b>408,148</b>	<b>318,276</b>

---

The profit and loss account has been prepared on the basis that all operations are continuing operations

There are no recognised gains and losses other than those passing through the profit and loss account



# RICHMOND PHARMACOLOGY LIMITED

## BALANCE SHEET

AS AT 31 DECEMBER 2010

	Notes	2010		2009	
		£	£	£	£
<b>Fixed assets</b>					
Tangible assets	7	633,688		696,310	
Investments	8		1		1
		<u>633,688</u>		<u>696,310</u>	
<b>Current assets</b>					
Debtors amounts falling due within one year	9	1,498,634	2,661,262		
Debtors amounts falling due after more than one year	9	130,000	130,000		
Cash at bank and in hand		<u>1,897,942</u>	<u>1,249,849</u>		
		3,526,576	4,041,111		
<b>Creditors amounts falling due within one year</b>	10	<u>(3,035,749)</u>	<u>(3,925,325)</u>		
<b>Net current assets</b>		<u>490,827</u>		<u>115,786</u>	
<b>Total assets less current liabilities</b>		<u>1,124,516</u>		<u>812,097</u>	
<b>Creditors: amounts falling due after more than one year</b>	11	<u>(21,116)</u>		<u>(116,845)</u>	
		<u>1,103,400</u>		<u>695,252</u>	
<b>Capital and reserves</b>					
Called up share capital	13	8,357		8,357	
Share premium account	14	359,500		359,500	
Profit and loss account	14	<u>735,543</u>		<u>327,395</u>	
<b>Shareholders' funds</b>	15	<u>1,103,400</u>		<u>695,252</u>	

Approved by the Board and authorised for issue on

12.07.2011

Dr R Arezina  
Director

Company Registration No 4269261

# RICHMOND PHARMACOLOGY LIMITED

## CASH FLOW STATEMENT

FOR THE YEAR ENDED 31 DECEMBER 2010

	£	2010 £	£	2009 £
<b>Net cash inflow from operating activities</b>		895,243		1,059,730
<b>Returns on investments and servicing of finance</b>				
Interest received	-		316	
Interest paid	(8,617)		(15,283)	
<b>Net cash outflow for returns on investments and servicing of finance</b>		(8,617)		(14,967)
<b>Capital expenditure and financial investment</b>				
Payments to acquire tangible assets	(108,552)		(86,703)	
Payments to acquire investments	-		(1)	
Receipts from sales of tangible assets	7,410		4,087	
<b>Net cash outflow for capital expenditure</b>		(101,142)		(82,617)
<b>Net cash inflow before management of liquid resources and financing</b>		785,484		962,146
<b>Financing</b>				
Repayment of long term bank loan	(66,110)		(238,190)	
Repayment of other long term loans	-		(20,004)	
Repayment of other short term loans	(18,317)		-	
Capital element of hire purchase contracts	(15,659)		(3,298)	
<b>Net cash outflow from financing</b>		(100,086)		(261,492)
<b>Increase in cash in the year</b>		685,398		700,654

# RICHMOND PHARMACOLOGY LIMITED

## NOTES TO THE CASH FLOW STATEMENT

FOR THE YEAR ENDED 31 DECEMBER 2010

<b>1</b>	<b>Reconciliation of operating profit to net cash inflow from operating activities</b>		<b>2010</b>	<b>2009</b>	
			<b>£</b>	<b>£</b>	
	Operating profit		416,765	333,243	
	Depreciation of tangible assets		200,614	186,535	
	Profit on disposal of tangible assets		(893)	-	
	Decrease/(increase) in debtors		1,162,628	(1,047,243)	
	(Decrease)/increase in creditors within one year		(883,871)	1,587,195	
	<b>Net cash inflow from operating activities</b>		<b>895,243</b>	<b>1,059,730</b>	
<b>2</b>	<b>Analysis of net funds</b>	<b>1 January 2010</b>	<b>Cash flow</b>	<b>Other non-cash changes</b>	<b>31 December 2010</b>
		<b>£</b>	<b>£</b>	<b>£</b>	<b>£</b>
	Net cash				
	Cash at bank and in hand	1,249,849	648,093	-	1,897,942
	Bank overdrafts	(60,651)	37,305	-	(23,346)
		<u>1,189,198</u>	<u>685,398</u>	<u>-</u>	<u>1,874,596</u>
	Debt				
	Finance leases	(8,009)	(20,298)	-	(28,307)
	Debts falling due within one year	(115,880)	(32,418)	-	(148,298)
	Debts falling due after one year	(116,845)	116,845	-	-
		<u>(240,734)</u>	<u>64,129</u>	<u>-</u>	<u>(176,605)</u>
	<b>Net funds</b>	<b>948,464</b>	<b>749,527</b>	<b>-</b>	<b>1,697,991</b>
<b>3</b>	<b>Reconciliation of net cash flow to movement in net funds</b>		<b>2010</b>	<b>2009</b>	
			<b>£</b>	<b>£</b>	
	Increase in cash in the year		685,398	700,654	
	Cash outflow from decrease in debt and lease financing		64,129	261,492	
	<b>Movement in net funds in the year</b>		<b>749,527</b>	<b>962,146</b>	
	Opening net funds/(debt)		948,464	(13,682)	
	<b>Closing net funds</b>		<b>1,697,991</b>	<b>948,464</b>	

# **RICHMOND PHARMACOLOGY LIMITED**

## **NOTES TO THE CASH FLOW STATEMENT (CONTINUED)**

***FOR THE YEAR ENDED 31 DECEMBER 2010***

---

### **4 Liquid resources**

Under Financial Reporting Standard 1, "Cash flow statements (revised 1996)", cash is defined as cash in hand, deposits repayable on demand without penalty and overdrafts. Short term deposits and investments are not considered to meet this definition and are therefore classified as liquid resources.

# **RICHMOND PHARMACOLOGY LIMITED**

## **NOTES TO THE FINANCIAL STATEMENTS**

**FOR THE YEAR ENDED 31 DECEMBER 2010**

---

### **1 Accounting policies**

#### **1.1 Accounting convention**

The financial statements are prepared under the historical cost convention

#### **1.2 Compliance with accounting standards**

The financial statements are prepared in accordance with applicable United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), which have been applied consistently (except as otherwise stated)

#### **1.3 Turnover**

Turnover represents the amounts invoiced to clients in line with the contractual obligations relating to each clinical trial study, net of Value Added Tax

Profit is recognised on each clinical trial study, if the final outcome can be assessed with reasonable certainty, by including in the profit and loss account the turnover and the related costs as each study progresses

#### **1.4 Tangible fixed assets and depreciation**

Tangible fixed assets are stated at cost less depreciation. Depreciation is provided at rates calculated to write off the cost less estimated residual value of each asset over its expected useful life, as follows

Leasehold buildings	over the period of the lease
Computer and medical equipment	over 3 - 10 years
Software cost	over 3 years
Fixtures, fittings & equipment	over 4 years
Motor vehicles	over 4 years

Software costs have not been depreciated as the software had not been brought into use at the balance sheet date

#### **1.5 Leasing and hire purchase commitments**

Assets obtained under hire purchase contracts and finance leases are capitalised as tangible assets and depreciated over the shorter of the lease term or their useful lives. Obligations under such agreements are included in creditors net of the finance charge allocated to future periods. The finance element of the rental payment is charged to the profit and loss account so as to produce a constant periodic rate of charge on the net obligation outstanding in each period

Rentals payable under operating leases are charged against income on a straight line basis over the lease term

#### **1.6 Investments**

Fixed asset investments are stated at cost less provision for diminution in value

#### **1.7 Long term contracts**

Amounts recoverable on long term contracts, which are included in debtors, are stated at the net sales value of the work done after provision for contingencies and anticipated future losses on contracts, less amounts received as progress payments on account. Excess progress payments are included in creditors as payments on account

# RICHMOND PHARMACOLOGY LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2010

---

**1 Accounting policies** (continued)

**1.8 Pensions**

The company operates a defined contribution scheme for the benefit of its employees. Contributions payable are charged to the profit and loss account in the year they are payable.

**1.9 Deferred taxation**

Where material, deferred tax is provided in full, as required by FRS 19 - Deferred Tax, in respect of timing differences between the treatment of certain items for taxation and accounting purposes.

**1.10 Foreign currency translation**

Monetary assets and liabilities denominated in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are recorded at the rate ruling at the date of the transaction. All differences are taken to profit and loss account.

**1.11 Group accounts**

The financial statements present information about the company as an individual undertaking and not about its group. Since the subsidiaries are not material and have remained dormant throughout the year, the company has taken advantage of the exemption provided by section 402 of the Companies Act 2006 not to prepare group accounts.

**2 Turnover**

The total turnover of the company for the year has been derived from its principal activity wholly undertaken in the United Kingdom.

<b>3 Operating profit</b>	<b>2010</b>	<b>2009</b>
	<b>£</b>	<b>£</b>
Operating profit is stated after charging		
Depreciation of tangible assets	200,614	186,535
Loss on foreign exchange transactions	-	451
Operating lease rentals	554,291	394,671
Auditors' remuneration (including expenses and benefits in kind)	25,038	19,082
and after crediting		
Profit on disposal of tangible assets	(893)	-
	<u>          </u>	<u>          </u>
<b>4 Investment income</b>	<b>2010</b>	<b>2009</b>
	<b>£</b>	<b>£</b>
Bank interest	-	316
	<u>          </u>	<u>          </u>
	-	316
	<u>          </u>	<u>          </u>

# RICHMOND PHARMACOLOGY LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2010

5 Interest payable	2010	2009
	£	£
On bank loans and overdrafts	6,209	13,888
Hire purchase interest	2,007	170
Other interest	401	1,225
	<u>8,617</u>	<u>15,283</u>
6 Taxation	2010	2009
<b>Current tax charge</b>	<u>-</u>	<u>-</u>
<b>Factors affecting the tax charge for the year</b>		
Profit on ordinary activities before taxation	<u>408,148</u>	<u>318,276</u>
Profit on ordinary activities before taxation multiplied by standard rate of UK corporation tax of 21.00% (2009 - 21.00%)	<u>85,711</u>	<u>66,838</u>
Effects of		
Non deductible expenses	738	2,154
Depreciation add back	42,129	39,172
Capital allowances	(19,557)	(10,647)
Research & development tax credit	(220,808)	(178,972)
Tax losses generated	111,787	81,455
	<u>(85,711)</u>	<u>(66,838)</u>
<b>Current tax charge</b>	<u>-</u>	<u>-</u>

The company has estimated tax losses of £4.1m (2009 £3.6m) available to carry forward. No provision for a deferred tax asset has been recognised on the basis that the asset is unlikely to be realised in the foreseeable future. The tax losses carried forward which have not been provided for would give rise to a potential deferred tax asset of £860,000 (2009 £750,000).

# RICHMOND PHARMACOLOGY LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2010

### 7 Tangible fixed assets

	Leasehold buildings	Computer and medical equipment	Software cost	Fixtures, fittings & equipment	Motor vehicles	Total
	£	£	£	£	£	£
<b>Cost</b>						
At 1 January 2010	1,136,639	1,309,238	70,000	81,328	16,460	2,613,665
Additions	-	142,044	-	2,465	-	144,509
Disposals	-	(5,831)	-	-	(16,460)	(22,291)
At 31 December 2010	1,136,639	1,445,451	70,000	83,793	-	2,735,883
<b>Depreciation</b>						
At 1 January 2010	993,093	838,011	-	74,935	11,316	1,917,355
On disposals	-	(3,429)	-	-	(12,345)	(15,774)
Charge for the year	71,773	124,815	-	2,997	1,029	200,614
At 31 December 2010	1,064,866	959,397	-	77,932	-	2,102,195
<b>Net book value</b>						
At 31 December 2010	71,773	486,054	70,000	5,861	-	633,688
At 31 December 2009	143,546	471,227	70,000	6,393	5,144	696,310

Included above are assets held under finance leases or hire purchase contracts as follows

	Medical equipment	Motor vehicles	Total
	£	£	£
<b>Net book values</b>			
At 31 December 2010	32,361	-	32,361
At 31 December 2009	-	5,144	5,144
<b>Depreciation charge for the year</b>			
At 31 December 2010	3,596	1,029	4,625
At 31 December 2009	-	4,115	4,115

Software costs have not been depreciated as the software had not been brought into use at the balance sheet date



# RICHMOND PHARMACOLOGY LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2010

### 8 Fixed asset investments

	Shares in subsidiary undertakings £
<b>Cost</b>	
At 1 January 2010 & at 31 December 2010	1
<b>Net book value</b>	
At 31 December 2010	1
At 31 December 2009	1

#### Holdings of more than 20%

The company holds more than 20% of the share capital of the following companies

Company	Country of registration or incorporation	Class	Shares held %
<b>Subsidiary undertakings</b>			
Richmond Pharmaceutical Services Limited	England and Wales	Ordinary	100
Prefect Limited	England and Wales	Ordinary	100

The aggregate amount of capital and reserves and the results of these undertakings for the last relevant financial year were as follows

		Capital and reserves 2010 £	Result for the year 2010 £
	<b>Principal activity</b>		
Richmond Pharmaceutical Services Limited	Dormant	1	-
Prefect Limited	Dormant	1	-

# RICHMOND PHARMACOLOGY LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2010

---

9 Debtors	2010	2009
	£	£
Trade debtors	1,118,976	1,687,234
Amounts recoverable on long term contracts	191,825	785,319
Other debtors	130,750	130,000
Prepayments and accrued income	187,083	188,709
	<u>1,628,634</u>	<u>2,791,262</u>

Amounts falling due after more than one year and included in the debtors above are

	2010	2009
	£	£
Other debtors	<u>130,000</u>	<u>130,000</u>

A rent deposit deed exists in favour of Mayday Healthcare NHS Trust to the value of £130,000

10 Creditors: amounts falling due within one year	2010	2009
	£	£
Bank loans and overdrafts	171,644	158,214
Payments received on account	1,140,831	2,248,032
Net obligations under hire purchase contracts	7,191	8,009
Trade creditors	938,575	1,017,569
Taxes and social security costs	158,641	178,353
Directors' current accounts	-	11,840
Other creditors	49,025	60,518
Accruals and deferred income	569,842	242,790
	<u>3,035,749</u>	<u>3,925,325</u>

There is a fixed and floating charge over the company's assets in favour of Barclays Bank plc. The amount outstanding at the year end was £171,644 (2009 £214,408). A Limited Guarantee amounting to £70,000 in aggregate has also been given to Barclays Bank plc jointly by Dr R Arezina, Dr J Taubel and Dr U Lorch.

# RICHMOND PHARMACOLOGY LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

### FOR THE YEAR ENDED 31 DECEMBER 2010

11 Creditors: amounts falling due after more than one year	2010 £	2009 £
Bank loans	-	116,845
Net obligations under hire purchase contracts	21,116	-
	<u>21,116</u>	<u>116,845</u>
<b>Analysis of loans</b>		
Wholly repayable within five years	148,298	232,725
	<u>148,298</u>	<u>232,725</u>
Included in current liabilities	(148,298)	(115,880)
	<u>-</u>	<u>116,845</u>
<b>Loan maturity analysis</b>		
In more than one year but not more than two years	-	116,845
	<u>-</u>	<u>116,845</u>
<b>Net obligations under hire purchase contracts</b>		
Repayable within one year	7,191	8,009
Repayable between one and five years	21,116	-
	<u>28,307</u>	<u>8,009</u>
Included in liabilities falling due within one year	(7,191)	(8,009)
	<u>21,116</u>	<u>-</u>
<b>12 Pension and other post-retirement benefit commitments</b>		
<b>Defined contribution</b>		
	2010 £	2009 £
Contributions payable by the company for the year	<u>32,823</u>	<u>37,250</u>

# RICHMOND PHARMACOLOGY LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2010

13 Share capital	2010 £	2009 £
<b>Authorised</b>		
1,000,000 A Ordinary shares of 5p each	50,000	50,000
1,000,000 B Ordinary shares of 5p each	50,000	50,000
	<u>100,000</u>	<u>100,000</u>
 <b>Allotted, called up and fully paid</b>		
93,600 A Ordinary shares of 5p each	4,680	4,680
73,543 B Ordinary shares of 5p each	3,677	3,677
	<u>8,357</u>	<u>8,357</u>

The A and B Ordinary shares rank pari passu in all respects

14 Statement of movements on reserves	Share premium account £	Profit and loss account £
Balance at 1 January 2010	359,500	327,395
Profit for the year	-	408,148
	<u>359,500</u>	<u>735,543</u>

15 Reconciliation of movements in shareholders' funds	2010 £	2009 £
Profit for the financial year	408,148	318,276
Opening shareholders' funds	695,252	376,976
	<u>1,103,400</u>	<u>695,252</u>

# RICHMOND PHARMACOLOGY LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2010

---

### 16 Financial commitments

At 31 December 2010 the company was committed to making the following payments under non-cancellable operating leases in the year to 31 December 2011

	Land and buildings	
	2010	2009
	£	£
Operating leases which expire		
Within one year	21,667	21,667
	<u>21,667</u>	<u>21,667</u>

### 17 Directors' emoluments

	2010	2009
	£	£
Emoluments for qualifying services	570,393	583,365
Company pension contributions to money purchase schemes	5,250	5,250
	<u>575,643</u>	<u>588,615</u>

Emoluments disclosed above include the following amounts paid to the highest paid director

Emoluments for qualifying services	<u>154,375</u>	<u>134,275</u>
------------------------------------	----------------	----------------

# RICHMOND PHARMACOLOGY LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2010

### 18 Employees

#### Number of employees

The average monthly number of employees (including directors) during the year was

	2010 Number	2009 Number
Number of clinical research staff	78	69
Number of administration staff	22	23
Number of management staff	4	4
	<u>104</u>	<u>96</u>

#### Employment costs

	2010 £	2009 £
Wages and salaries	4,674,441	3,834,057
Social security costs	463,549	396,612
Other pension costs	32,823	37,250
	<u>5,170,813</u>	<u>4,267,919</u>

### 19 Related party transactions

At the balance sheet date the company owed Chester Overseas Limited £Nil (2009 £18,317) by way of a loan, on which interest of £408 (2009 £1,225) was paid in the year. The families of Mr L Levine and Mr M Levine have an interest in Chester Overseas Limited.